The Walter Reed Army Institute of Research enlisted 39 healthy volunteers for the trial, and injected the first subject with the VSV-EBOV vaccine in phase 1 of testing Monday.
Canada supplied 20 vials of the vaccine for the trial, which medical officials will be monitoring predominately throughout the phase 1 trial for safety, and also to determine proper dosage level.
Officials divided the volunteers into three groups, the first of which received a low-dose of the vaccination and will need medical clearance from a safety commission, at which point the second group can receive the intermediate-dose. The second group will go through the same procedure, which includes blood tests to determine antibody production and monitoring for possible side effects before the third group is cleared to receive what is considered a high-dose, Col. Shon Remich of Walter Reed Army Institute of Research told FoxNews.com.
Join the conversation as a VIP Member